Show simple item record

dc.contributor.authorWatsierah, Carren A
dc.contributor.authorOuma, Collins
dc.date.accessioned2018-01-22T11:34:43Z
dc.date.available2018-01-22T11:34:43Z
dc.date.issued2014-07-28
dc.identifier.urihttps://repository.maseno.ac.ke/handle/123456789/175
dc.description.abstractArtemisinin-based combination therapy (ACT) has been adopted as the most effective treatment against malaria in many endemic countries like Kenya while quinine has remained the second line. The objective of the current study was to assess access to Kenya's policy recommended anti-malarials, ACT and quinine in the public, private and not- for-profit drug outlets in western Kenya. Methods A cross-sectional survey using purposive sampling of 288 outlets (126 public, 96 private, 66 not-for-profit) was conducted in western Kenya in two regions with varying Plasmodium falciparum endemicities. Information on access (availability, price, affordability) on ACT and quinine was collected using the WHO and Healthcare Associated Infection (HAI) standardized methodologies for availability, prices and affordability of drugs. From a Ministry of Health database, the following were …en_US
dc.publisherBioMed Centralen_US
dc.titleAccess to artemisinin-based combination therapy (ACT) and quinine in malaria holoendemic regions of western Kenyaen_US
dc.typeArticleen_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record